{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T06:19:05Z","timestamp":1794550745533,"version":"4.9.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ministry of Health & Welfare, Republic of Korea","award":["1720160"],"award-info":[{"award-number":["1720160"]}]},{"name":"Chonnam National University Hwasun Hospital Institute for Biomedical Science","award":["HCRI24037"],"award-info":[{"award-number":["HCRI24037"]}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2018R1A2A1A05078480"],"award-info":[{"award-number":["2018R1A2A1A05078480"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"crossref","award":["RS-2025-24536036"],"award-info":[{"award-number":["RS-2025-24536036"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Antithymocyte globulin (ATG) reduces chronic graft-versus-host disease (cGvHD), but concerns remain regarding relapse risk, particularly across cytogenetic risk groups. We retrospectively analyzed 148 acute myeloid leukemia (AML) patients in first remission who underwent matched sibling allogeneic hematopoietic stem cell transplantation (HSCT) across three centers. Patients received transplantation with or without ATG (2.5\u20135\u00a0mg\/kg) and were stratified by cytogenetic risk (intermediate,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009128; adverse,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200920). Propensity score matching and inverse probability of treatment weighting were applied to adjust for baseline imbalances. After a median follow-up of 91 months, ATG use (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200996) reduced the incidence of cGvHD (HR 0.43; 95% CI 0.26\u20130.72;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.001) and improved cGvHD-free relapse-free survival (cGRFS; HR 0.61; 95% CI 0.40\u20130.93;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.022). No significant differences were observed in overall survival, event-free survival (EFS), relapse, or non-relapse mortality. A significant interaction between ATG and cytogenetic risk (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.025) indicated differential effects by risk profiles. In subgroup analyses, intermediate-risk patients derived consistent benefit, whereas adverse-risk patients (ATG\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200912; non-ATG\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20098) showed higher relapse and inferior EFS. With respect to dose, both 2.5 and 5\u00a0mg\/kg reduced cGvHD relative to non-ATG; exploratory analyses suggested that 2.5\u00a0mg\/kg may provide adequate prophylaxis without excess relapse, although statistical power was limited. In conclusion, ATG was associated with reduced cGvHD and improved cGRFS in HSCT for AML, with benefit mainly in intermediate-risk patients. Its use in adverse-risk AML warrants caution, as it may be associated with higher relapse.\n                  <\/jats:p>","DOI":"10.1007\/s00277-025-06608-3","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T08:00:39Z","timestamp":1760601639000},"page":"5995-6004","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cytogenetic risk\u2013associated outcomes of antithymocyte globulin use in HLA-matched sibling transplantation for acute myeloid leukemia"],"prefix":"10.1007","volume":"104","author":[{"given":"Mihee","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ik-Chan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seo-Yeon","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Cheol","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Suk","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeoung-Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho-Young","family":"Yhim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Sook","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"issue":"1","key":"6608_CR1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","volume":"127","author":"JJ Cornelissen","year":"2016","unstructured":"Cornelissen JJ, Blaise D (2016) Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood 127(1):62\u201370","journal-title":"Blood"},{"issue":"1","key":"6608_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s44313-024-00041-7","volume":"59","author":"T Tan","year":"2024","unstructured":"Tan T, Bozdag SC (2024) How to improve AML outcomes? Blood Res 59(1):39","journal-title":"Blood Res"},{"issue":"1","key":"6608_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1056\/NEJM199907013410103","volume":"341","author":"G Socie","year":"1999","unstructured":"Socie G, Stone JV, Wingard JR, Weisdorf D, Henslee-Downey PJ, Bredeson C, Late effects working committee of the international bone marrow transplant registry et al (1999) Long-term survival and late deaths after allogeneic bone marrow transplantation. N Engl J Med 341(1):14\u201321","journal-title":"N Engl J Med"},{"issue":"1","key":"6608_CR4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.5045\/br.2023.2022192","volume":"58","author":"MJ Tavaf","year":"2023","unstructured":"Tavaf MJ, Verkiani ME, Hanzaii FP, Zomorrod MS (2023) Effects of immune system cells in GvHD and corresponding therapeutic strategies. Blood Res 58(1):2\u201312","journal-title":"Blood Res"},{"issue":"36","key":"6608_CR5","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1200\/JCO.2017.75.8177","volume":"35","author":"RJ Soiffer","year":"2017","unstructured":"Soiffer RJ, Kim HT, McGuirk J, Horwitz ME, Johnston L, Patnaik MM et al (2017) Prospective, randomized, double-blind, phase III clinical trial of anti\u2013T-lymphocyte globulin to assess impact on chronic graft-versus-host disease\u2013free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. J Clin Oncol 35(36):4003\u20134011","journal-title":"J Clin Oncol"},{"issue":"2","key":"6608_CR6","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S1470-2045(15)00462-3","volume":"17","author":"I Walker","year":"2016","unstructured":"Walker I, Panzarella T, Couban S, Couture F, Devins G, Elemary M et al (2016) Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncol 17(2):164\u2013173","journal-title":"Lancet Oncol"},{"issue":"10","key":"6608_CR7","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1038\/s41409-019-0502-8","volume":"54","author":"Y Luo","year":"2019","unstructured":"Luo Y, Jin M, Tan Y, Zhao Y, Shi J, Zhu Y et al (2019) Antithymocyte globulin improves GVHD-free and relapse-free survival in unrelated hematopoietic stem cell transplantation. Bone Marrow Transplant 54(10):1668\u20131675","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"6608_CR8","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/s41409-020-01121-9","volume":"56","author":"HM Kang","year":"2021","unstructured":"Kang HM, Kim SK, Lee JW, Chung NG, Cho B (2021) Efficacy of low dose antithymocyte globulin on overall survival, relapse rate, and infectious complications following allogeneic peripheral blood stem cell transplantation for leukemia in children. Bone Marrow Transplant 56(4):890\u2013899","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"6608_CR9","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1016\/j.bbmt.2018.12.126","volume":"25","author":"A Nagler","year":"2019","unstructured":"Nagler A, Labopin M, Soci\u00e9 G, Huynh A, It\u00e4l\u00e4-Remes M, Deconinck E et al (2019) The role of anti-thymocyte globulin (ATG) in patients with AML transplanted in CR1 from sibling and unrelated donors with or without measurable residual disease (MRD) at the time of allogeneic stem cell transplantation: a study on behalf of the acute leukemia working party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Biol Blood Marrow Transplant 25(3):S48\u2013S9","journal-title":"Biol Blood Marrow Transplant"},{"key":"6608_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2024.102131","volume":"87","author":"L Deng","year":"2024","unstructured":"Deng L, Yu X, Song X, Guan R, Li W, Liu X et al (2024) The prophylactic application of low-dose rabbit antithymocyte globulin in matched siblings HSCT with high-risk factors for graft-versus-host disease. Transpl Immunol 87:102131","journal-title":"Transpl Immunol"},{"issue":"11","key":"6608_CR11","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1002\/ajh.26320","volume":"96","author":"BS Cho","year":"2021","unstructured":"Cho BS, Min GJ, Park SS, Yoon SY, Park S, Jeon YW et al (2021) Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. Am J Hematol 96(11):1441\u20131449","journal-title":"Am J Hematol"},{"issue":"25","key":"6608_CR12","doi-asserted-by":"publisher","first-page":"6963","DOI":"10.1182\/blood-2011-01-332007","volume":"117","author":"RJ Soiffer","year":"2011","unstructured":"Soiffer RJ, Lerademacher J, Ho V, Kan F, Artz A, Champlin RE et al (2011) Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 117(25):6963\u20136970","journal-title":"Blood"},{"issue":"3","key":"6608_CR13","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/bmt.2013.204","volume":"49","author":"F Baron","year":"2014","unstructured":"Baron F, Labopin M, Blaise D, Lopez-Corral L, Vigouroux S, Craddock C et al (2014) Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the acute leukemia working party of the European group for blood and marrow transplantation. Bone Marrow Transplant 49(3):389\u2013396","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"6608_CR14","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41409-017-0043-y","volume":"53","author":"R Devillier","year":"2018","unstructured":"Devillier R, Labopin M, Chevallier P, Ledoux MP, Soci\u00e9 G, Huynh A et al (2018) Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of bone marrow transplantation. Bone Marrow Transplant 53(4):431\u2013437","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"6608_CR15","doi-asserted-by":"publisher","first-page":"E368","DOI":"10.1111\/ctr.12131","volume":"27","author":"M Remberger","year":"2013","unstructured":"Remberger M, Ringden O, Hagglund H, Svahn BM, Ljungman P, Uhlin M et al (2013) A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors. Clin Transpl 27(4):E368\u2013E374","journal-title":"Clin Transpl"},{"issue":"3","key":"6608_CR16","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/ajh.27195","volume":"99","author":"M Teramoto","year":"2024","unstructured":"Teramoto M, Takahashi T, Matsumoto K, Jaber M, Kaida K, Tamaki H et al (2024) Individualized rabbit anti-thymocyte Globulin dosing in adult haploidentical hematopoietic cell transplantation with high-risk hematologic malignancy: exposure-response analysis and population pharmacokinetics simulations. Am J Hematol 99(3):387\u2013395","journal-title":"Am J Hematol"},{"issue":"23","key":"6608_CR17","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1182\/blood-2016-06-721936","volume":"128","author":"R Admiraal","year":"2016","unstructured":"Admiraal R, Lindemans CA, van Kesteren C, Bierings MB, Versluijs AB, Nierkens S et al (2016) Excellent T-cell reconstitution and survival depend on low ATG exposure after pediatric cord blood transplantation. Blood 128(23):2734\u20132741","journal-title":"Blood"},{"issue":"2","key":"6608_CR18","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.1016\/S2352-3026(21)00375-6","volume":"9","author":"R Admiraal","year":"2022","unstructured":"Admiraal R, Nierkens S, Bierings MB, Bredius RGM, van Vliet I, Jiang Y et al (2022) Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial. Lancet Haematol 9(2):e111\u2013e20","journal-title":"Lancet Haematol"},{"issue":"4","key":"6608_CR19","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1016\/S2352-3026(17)30029-7","volume":"4","author":"R Admiraal","year":"2017","unstructured":"Admiraal R, Nierkens S, de Witte MA, Petersen EJ, Fleurke GJ, Verrest L et al (2017) Association between anti-thymocyte Globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis. Lancet Haematol 4(4):e183\u2013e91","journal-title":"Lancet Haematol"},{"key":"6608_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cells12141831","author":"A Nikoloudis","year":"2023","unstructured":"Nikoloudis A, Buxhofer-Ausch V, Aichinger C, Binder M, Hasengruber P, Kaynak E et al (2023) Impact of the recipient\u2019s pre-treatment blood lymphocyte count on intended and unintended effects of anti-T-lymphocyte globulin in allogeneic hematopoietic stem cell transplantation. Cells 12(14):1831.\u00a0https:\/\/doi.org\/10.3390\/cells12141831","journal-title":"Cells"},{"issue":"3","key":"6608_CR21","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","volume":"116","author":"D Grimwade","year":"2010","unstructured":"Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH et al (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116(3):354\u2013365","journal-title":"Blood"},{"issue":"12","key":"6608_CR22","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u20131377","journal-title":"Blood"},{"issue":"3","key":"6608_CR23","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48(3):452\u2013458","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"6608_CR24","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1182\/blood.V98.10.2942","volume":"98","author":"A Bacigalupo","year":"2001","unstructured":"Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P et al (2001) Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 98(10):2942\u20132947","journal-title":"Blood"},{"issue":"8","key":"6608_CR25","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/sj.bmt.1701991","volume":"24","author":"M Remberger","year":"1999","unstructured":"Remberger M, Svahn BM, Hentschke P, Lofgren C, Ringden O (1999) Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant 24(8):823\u2013830","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"6608_CR26","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S1470-2045(17)30417-5","volume":"18","author":"F Locatelli","year":"2017","unstructured":"Locatelli F, Bernardo ME, Bertaina A, Rognoni C, Comoli P, Rovelli A et al (2017) Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 18(8):1126\u20131136","journal-title":"Lancet Oncol"},{"issue":"1","key":"6608_CR27","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.bbmt.2017.08.029","volume":"24","author":"VE Kennedy","year":"2018","unstructured":"Kennedy VE, Chen H, Savani BN, Greer J, Kassim AA, Engelhardt BG et al (2018) Optimizing antithymocyte Globulin dosing for unrelated donor allogeneic hematopoietic cell transplantation based on recipient absolute lymphocyte count. Biol Blood Marrow Transpl 24(1):150\u2013155","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"6608_CR28","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/ajt.15642","volume":"20","author":"AT Turki","year":"2020","unstructured":"Turki AT, Klisanin V, Bayraktar E, Kordelas L, Trenschel R, Ottinger H et al (2020) Optimizing anti-T-lymphocyte globulin dosing to improve long-term outcome after unrelated hematopoietic cell transplantation for hematologic malignancies. Am J Transplant 20(3):677\u2013688","journal-title":"Am J Transplant"},{"issue":"9","key":"6608_CR29","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.clml.2021.05.003","volume":"21","author":"MM Ali","year":"2021","unstructured":"Ali MM, Gronvold B, Remberger M, Abrahamsen IW, Myhre AE, Tjonnfjord GE et al (2021) Addition of Anti-thymocyte Globulin in allogeneic stem cell transplantation with peripheral stem cells from matched unrelated donors improves Graft-Versus-Host disease and relapse free survival. Clin Lymphoma Myeloma Leuk 21(9):598\u2013605","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"24","key":"6608_CR30","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1016\/j.scib.2021.06.002","volume":"66","author":"Y Wang","year":"2021","unstructured":"Wang Y, Liu QF, Lin R, Yang T, Xu YJ, Mo XD et al (2021) Optimizing antithymocyte globulin dosing in haploidentical hematopoietic cell transplantation: long-term follow-up of a multicenter, randomized controlled trial. Sci Bull 66(24):2498\u20132505","journal-title":"Sci Bull"},{"issue":"1","key":"6608_CR31","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/bloodadvances.2021005509","volume":"6","author":"AT Turki","year":"2022","unstructured":"Turki AT, Tsachakis-Muck N, Leserer S, Crivello P, Liebregts T, Betke L et al (2022) Impact of CMV reactivation on relapse of acute myeloid leukemia after HCT is dependent on disease stage and ATG. Blood Adv 6(1):28\u201336","journal-title":"Blood Adv"},{"issue":"6","key":"6608_CR32","doi-asserted-by":"publisher","first-page":"E117","DOI":"10.1002\/ajh.23998","volume":"90","author":"A Busca","year":"2015","unstructured":"Busca A, Passera R, Pini M, Zallio F, Dellacasa C, Audisio E et al (2015) The use of ATG abrogates the antileukemic effect of cytomegalovirus reactivation in patients with acute myeloid leukemia receiving grafts from unrelated donors. Am J Hematol 90(6):E117\u2013E121","journal-title":"Am J Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06608-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06608-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06608-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T02:31:27Z","timestamp":1764729087000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06608-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":32,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["6608"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06608-3","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]},"assertion":[{"value":"18 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional ethics committees of participating institutions and was conducted in accordance with the Declaration of Helsinki. The institutional ethics committees waived the requirement for informed patient consent owing to the retrospective study design.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}